Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine

Manóchio, Caíque; Torres-Loureiro, Sabrina; Scudeler, Mariana M; Miwa, Bruno; Souza-Santos, Fernanda C; Rodrigues‐Soares, Fernanda

doi:10.1089/omi.2022.0151

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Major pathophysiological features of liver injury in SARS-CoV-2 infection include hepatic lobular and portal inflammation, steatosis, congestion, focal necrosis with neutrophil infiltration, microthrombosis, and mild-to-moderate increases in liver aminotransferase (five times the upper limit of normal {ULN}) [ 33 ]. Remdesivir use in SARS-CoV-2 patients is associated with mild-to-moderate self-limiting hepatic injury, with no signs of jaundice [ 34 ]. Our study reported a statistically significant increase (p=0.003) in ALT in 54.5% of patients, while there were non-significant increases in AST seen in 45.5% of COVID-19-recovered patients after using remdesivir.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province

Ayyashi¹,

Darbashi²,

Khalid³

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 , has spread around the world, spurring the biomedical community to find and create antiviral therapies. The agent remdesivir, which has undergone a protracted and tortuous developmental path, is one potential therapeutic strategy now being assessed in several clinical trials. A broad-spectrum antiviral drug called remdesivir has already shown antiviral effects against filoviruses. Remdesivir was suggested as an exploratory medicine early in the pandemic because in vitro tests showed it to have antiviral effectiveness against SARS-CoV-2. MethodsWe conducted a retrospective cohort study that examined patient data captured through an electronic medical system at the Abu Arish General Hospital between 2021 and 2022. Data analysis was performed with SPSS version 25.0 (Armonk, NY: IBM Corp.). ResultsA total of 88 patients were included in this study. With the usage of remdesivir, our risk model is able to forecast adverse events and the case fatality rate. In contrast to D-dimer and c-reactive proteins, we showed that alanine transaminase (ALT), aspartate aminotransferase (AST), serum creatinine, and hemoglobin are relevant variables. ConclusionOur risk model can predict the adverse reactions and case fatality rate with the use of remdesivir. We demonstrated ALT, AST, serum creatinine, and hemoglobin as important variables rather than D-dimer and c-reactive proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province

Ayyashi¹,

Darbashi²,

Khalid³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Role of Molnupiravir in the Treatment of COVID-19

Patil¹,

Sharma²,

Dahiya

et al. 2023

AIA

View full text Add to dashboard Cite

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by inhibiting replication. Preclinical studies have been reported that support the role of Molnupiravir towards the prophylaxis, cure, and prevention of SARS-CoV-2 infection. In addition to it, clinical studies have confirmed its activity against the most common variants of SARS-CoV-2. Objective: The manuscript aims to demonstrate the rationale behind the clinical use of Molnupiravir in the treatment of COVID-19 infection at the early stage of the onset of symptoms specific to five days. Methodology: A thorough literature search has been carried out using various suitable keywords to extract details on the antiviral mechanism, preclinical, and clinical use of Molnupiravir, its safety, tolerability, dosage, duration of treatment, etc. Results: The reported studies demonstrate the antiviral action of Molnupiravir by viral error catastrophe mechanism which results in the inhibition of the viral multiplication activity when it enters inside the host cells. The manuscript delivers complete detail regarding pharmacokinetic and pharmacological actions, usage, and various preclinical and clinical studies reported for this newly evaluated drug for the treatment of COVID-19 infection. Conclusion: The study concludes Molnupiravir has the potential in the treatment of COVID-19 infection. When used along with vaccines, it would be a low-cost, valuable, and incredible asset as an oral anti-COVID drug for saving human life.

show abstract

Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine

Cited by 2 publications

References 63 publications

Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province

Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province

Role of Molnupiravir in the Treatment of COVID-19

Contact Info

Product

Resources

About